Abstract Details

Title Patient and Treatment Characteristics of a Large US Sample of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Initiating Intravenous Immunoglobulin (IVIG) Therapy

Topic Autoimmune Neurology

Presentation(s) Autoimmune Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 063

Objective We aimed to identify and describe demographic and clinical characteristics of patients with CIDP in the US initiating IVIG treatment.

Background IVIG is first-line therapy for CIDP, a rare immune-mediated neuropathy. The clinical profile of patients with CIDP newly initiating IVIG is not well characterized.

Design/Methods This claims-based cohort study identified immunoglobulin-naïve adults with CIDP from 2008–2018 via diagnosis coding using the IBM® MarketScan® Research Databases. Within the full CIDP cohort, patients who subsequently initiated IVIG therapy were identified. Clinical and demographic characteristics of these new IVIG users were described overall and by initial IVIG product.

Results Demographics were similar between new IVIG users (n=3975) and the full CIDP cohort (N=32 090). However, new IVIG users versus the full CIDP cohort tended to have greater comorbidity and symptom burdens, which included weakness (31% vs 17%), difficulty walking (30% vs 18%), neuropathic/chronic pain (80% vs 64%), diabetes (33% vs 29%), hypertension (62% vs 52%), hypothyroidism (22% vs 18%), rheumatoid arthritis (19% vs 14%), and other autoimmunity disorders (7% vs 3%), respectively. Median age of new IVIG users was 58 years, 59% were male. Almost all new IVIG use (99%) was started in an ambulatory setting; 35% new IVIG users had prior treatment with high-dose corticosteroids. New IVIG users were more likely than full CIDP cohort to have had an electrodiagnostic/nerve conduction testing, magnetic resonance imaging, or computed tomography. Clinical and demographic characteristics were similar among patients by initial IVIG product, except for US region and calendar year of index treatment.

Conclusions There was a trend to initiate IVIG in patients with CIDP who had greater comorbidity and symptom burdens. No correlation was observed between patient characteristics and selection of initial IVIG treatment; rather, differences in selection varied by year and region. Baxalta US Inc. (a Takeda company) funded this study and writing support.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Shailesh Chavan	Shailesh Chavan has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Shailesh Chavan has received stock or an ownership interest from Takeda Pharmaceuticals.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��